73,621 Shares in Prenetics Global Limited $PRE Purchased by Aberdeen Group plc

Aberdeen Group plc purchased a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 73,621 shares of the company’s stock, valued at approximately $979,000. Aberdeen Group plc owned 0.44% of Prenetics Global at the end of the most recent reporting period.

Separately, Stevens Capital Partners purchased a new position in shares of Prenetics Global during the second quarter valued at approximately $137,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Price Performance

NASDAQ:PRE opened at $17.05 on Friday. The firm has a market capitalization of $286.95 million, a P/E ratio of -4.24 and a beta of 0.35. Prenetics Global Limited has a one year low of $3.09 and a one year high of $22.86. The company’s 50-day simple moving average is $17.80 and its 200 day simple moving average is $14.02.

Prenetics Global (NASDAQ:PRE) last released its earnings results on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.22. The firm had revenue of $36.60 million during the quarter, compared to analyst estimates of $36.15 million. Prenetics Global had a negative net margin of 61.33% and a negative return on equity of 19.07%. On average, equities research analysts expect that Prenetics Global Limited will post -3.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PRE shares. Roth Mkm started coverage on Prenetics Global in a research note on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald boosted their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $34.00.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.